A Single Amino Acid Change Makes Exendin-4 a Better Imaging Probe with Less Hypoglycemia Risk

Researchers synthesized exendin-4 and Ex-D3 derivatives with C-terminal cysteine additions for site-specific iodine-125 labeling. Binding affinity was assessed using surface plasmon resonance. In vivo studies in mice measured blood glucose effects and biodistribution of the radiolabeled peptides. Ex vivo autoradiography confirmed binding specificity to GLP-1R-expressing pancreatic beta cells.

Imaging GLP-1 receptors is clinically important for diagnosing insulinomas, monitoring beta cell mass in diabetes, and evaluating transplanted islet cells. Current exendin-4-based probes carry a risk of dangerous hypoglycemia that limits their use. A probe that images better while being safer could expand clinical applications of GLP-1R imaging and benefit patients who most need it.

As GLP-1 receptor biology becomes central to diabetes and obesity treatment, the ability to image these receptors non-invasively gains importance. Better imaging probes could help diagnose insulinomas, monitor beta cell mass during diabetes progression, track transplanted islet cells, and potentially guide GLP-1 drug therapy. This study demonstrates that even minimal peptide modifications can significantly improve both efficacy and safety of molecular imaging tools.

This is a preclinical mouse study with no human data. The comparison was limited to iodine-125 labeling; other radioisotopes commonly used in clinical imaging (gallium-68, fluorine-18) were not tested. Long-term toxicity and immunogenicity were not assessed. The study does not quantify the degree of hypoglycemia reduction in absolute terms. Translation to human imaging would require further development and clinical validation.